Evidence map›Paper›PMID 39172332›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

Overexpression of cytoplasmic poly(A)-binding protein 1 as a biomarker for the prognosis and selection of postoperative regimen in breast cancer.

Yunqiu Wu, Yi Quan, Dan Zhou, Yixian Li, Xue Wen, Jun Liu, Wenbo Long

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yunqiu WuDepartment of Breast Surgery, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Yi QuanDepartment of Breast Surgery, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Dan ZhouDepartment of Breast Surgery, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Yixian LiDepartment of Breast Surgery, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Xue WenDepartment of Pathology, The Affiliated Hospital, Southwest Medical University, Jiangyang District, Taiping Street No. 25, Luzhou, China.
Jun LiuDepartment of Pathology, The Affiliated Hospital, Southwest Medical University, Jiangyang District, Taiping Street No. 25, Luzhou, China.
Wenbo LongDepartment of Pathology, The Affiliated Hospital, Southwest Medical University, Jiangyang District, Taiping Street No. 25, Luzhou, China. wenbolong@swmu.edu.cn.ORCID http://orcid.org/0000-0002-9647-685X

Funding

Application foundation project of Luzhou science and technology and talent Bureau 2021-JYJ-65Joint project of Luzhou City and Southwest Medical University 2018LZXNYD-ZK22University level funding program of Southwest Medical University 2019ZQN055
6 · The paper itself

Abstract

purposeThe dysregulation of the cytoplasmic poly(A)-binding protein 1 (PABPC1) is involved in a variety of tumors but little is known about its role in human breast cancer. Therefore, the effect of PABPC1 in the prognosis and regimen selection in breast cancer patients was evaluated.

methodsA total of 791 cases of invasive breast cancer were included in this study, although only 416 were involved in subsequent analyses after the propensity score matching (PSM) test. PABPC1 expression was detected by immunohistochemistry. The relationship between PABPC1 expression and clinicopathological factors, postoperative regimens, and outcomes was determined.

resultsIn the total 791 cases, 583 cases were positive for PABPC1, but only 212 (26.8%) showed high PABPC1 expression (PABPC1-HE). The overall survival (OS) and disease-free survival (DFS) of PABPC1-HE patients after PSM were significantly worse than those in patients with PABPC1 low expression (PABPC1-LE), regardless of age, molecular type, tumor size, nodal status, or pStage. Postoperative chemotherapy (CT) increased the OS of PABPC1-HE patients but not that of PABPC1-LE patients. Among patients receiving endocrine therapy, those in the PABPC-LE group had an extended OS, while CT or chemoradiotherapy (CT/CRT) only significantly extended the OS time of PABPC-HE patients. CT/CRT did not significantly extend the survival of PABPC1-LE HER2-positive patients but extended the OS of PABPC1-HE HER2-positive patients. However, the OS of patients treated with CT/CRT + trastuzumab therapy was significantly longer than that of other patients under other therapies in the PABPC1-HE group, suggesting that PABPC1-HE might be sensitive to trastuzumab-based therapy. The multivariate analysis revealed that PABPC1-HE was an independent prognostic factor for both poor OS and DFS in breast cancer except luminal A type.

conclusionsOur results revealed that PABPC1 might be considered as a biomarker to help in subtyping, as well as in the prognosis and regimen selection of breast cancer patients.

Indexed as

Biomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastPoly(A)-Binding Protein IAdultAgedChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansMiddle AgedPrognosisRetrospective StudiesSurvival RateBiomarkers, TumorPoly(A)-Binding Protein IAnti-HER2 therapyBreast cancerCytoplasmic poly(A)-binding protein 1Endocrine therapyPrognosis and regimen selection

Identifiers

PMID39172332

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.